Long-Acting Beta2-Agonist and Inhaled Corticosteroid Combination Therapy for Adult Persistent Asthma: Systematic Review of Clinical Outcomes and Economic Evaluation
CADTH’s health technology assessment report on long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination therapy examines the clinical efficacy, safety, and cost-effectiveness of this treatment strategy for adult persistent asthma. This assessment focuses on LABA-ICS combination therapy and its place in therapy. The report also looks at current clinical practice guidelines and the health services impact of different treatment options.
This complete report has been extensively peer-reviewed by external clinical and methodological experts.
- Technology Report (351 pages)